OBJECTIVE: Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis. This study investigated the involvement of tumor necrosis factor receptor-associated factors (TRAFs) in CD40 signaling in endothelial cells (ECs) and their expression in atheromata and cells involved in atherogenesis. METHODS AND RESULTS: CD40L enhanced the basal expression of TRAF-1, -2, -3, and 6, but not TRAF-5 in ECs. TRAFs associated with CD40 on ligation by CD40L. Study of ECs from TRAF-1, -2, and -5-deficient mice demonstrated functional involvement of TRAFs in proinflammatory CD40 signaling. Whereas TRAF-1 deficiency enhanced CD40L-induced IL-6 and MCP-1 expression, TRAF-2 and TRAF-5 deficiency inhibited CD40L-inducible IL-6 but not MCP-1 expression. Gene silencing in human ECs further delineated functions of TRAFs in CD40 signaling. TRAF-3 silencing in ECs showed increased CD40L-induced IL-6, MCP-1, and IL-8 expression, whereas TRAF-6 silencing increased selectively CD40L-induced MCP-1 expression. Enhanced TRAF levels in atherosclerotic lesions further supports involvement of members of this family of signaling molecules in arterial disease. CONCLUSIONS: These results implicate endothelial TRAF-1, -2, -3, -5, and -6 in CD40 signaling in atherogenesis, identifying these molecules as potential targets for selective therapeutic intervention.
OBJECTIVE: Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis. This study investigated the involvement of tumor necrosis factor receptor-associated factors (TRAFs) in CD40 signaling in endothelial cells (ECs) and their expression in atheromata and cells involved in atherogenesis. METHODS AND RESULTS:CD40L enhanced the basal expression of TRAF-1, -2, -3, and 6, but not TRAF-5 in ECs. TRAFs associated with CD40 on ligation by CD40L. Study of ECs from TRAF-1, -2, and -5-deficient mice demonstrated functional involvement of TRAFs in proinflammatory CD40 signaling. Whereas TRAF-1 deficiency enhanced CD40L-induced IL-6 and MCP-1 expression, TRAF-2 and TRAF-5 deficiency inhibited CD40L-inducible IL-6 but not MCP-1 expression. Gene silencing in human ECs further delineated functions of TRAFs in CD40 signaling. TRAF-3 silencing in ECs showed increased CD40L-induced IL-6, MCP-1, and IL-8 expression, whereas TRAF-6 silencing increased selectively CD40L-induced MCP-1 expression. Enhanced TRAF levels in atherosclerotic lesions further supports involvement of members of this family of signaling molecules in arterial disease. CONCLUSIONS: These results implicate endothelial TRAF-1, -2, -3, -5, and -6 in CD40 signaling in atherogenesis, identifying these molecules as potential targets for selective therapeutic intervention.
Authors: Robert C Huebert; Kumaravelu Jagavelu; Ann F Liebl; Bing Q Huang; Patrick L Splinter; Nicholas F LaRusso; Raul A Urrutia; Vijay H Shah Journal: Lab Invest Date: 2010-07-19 Impact factor: 5.662
Authors: Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop Journal: Immunol Rev Date: 2011-11 Impact factor: 12.988
Authors: Anguo Liu; Ping Gong; Sang W Hyun; Kent Z Q Wang; Elizabeth A Cates; Darren Perkins; Douglas D Bannerman; Adam C Puché; Vladimir Y Toshchakov; Shengyun Fang; Philip E Auron; Stefanie N Vogel; Simeon E Goldblum Journal: J Biol Chem Date: 2012-03-23 Impact factor: 5.157
Authors: Jose-Andres C Portillo; Jennifer A Greene; Isaac Schwartz; Maria Cecilia Subauste; Carlos S Subauste Journal: Immunology Date: 2015-01 Impact factor: 7.397
Authors: Esther Lutgens; Dirk Lievens; Linda Beckers; Erwin Wijnands; Oliver Soehnlein; Alma Zernecke; Tom Seijkens; David Engel; Jack Cleutjens; Anna M Keller; Shalin H Naik; Louis Boon; Hafid Ait Oufella; Ziad Mallat; Cory L Ahonen; Randolph J Noelle; Menno P de Winther; Mat J Daemen; Erik A Biessen; Christian Weber Journal: J Exp Med Date: 2010-01-25 Impact factor: 14.307